Nammi Therapeutics Inc. has divulged prodrugs of Toll-like receptor (TLR) agonists and its self-assembled lipid nanoparticles reported to be useful for the treatment of cancer and immunological disorders.
Scinnohub Pharmaceutical Co. Ltd. has identified S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer.
Shanghai Ringene Biopharma Co. Ltd. has synthesized CDK7/cyclin H inhibitors reported to be useful for the treatment of cancer, hemolytic anemia, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, sepsis, idiopathic thrombocytopenic purpura and ulcerative colitis, among others.
JS Innomed Holdings Ltd. has disclosed heterocyclic compounds acting as tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of cancer, LEOPARD syndrome and Noonan syndrome.
Current therapies based on immune checkpoint blockade are effective and offer a valid option for treatment, but many patients develop either primary or acquired resistance to treatment. Previous research has shown that the deletion of protein tyrosine phosphatases PTPN2 and PTPN1 results in an increase in the sensitization of tumor cells and the promotion of antitumor immunity.
Protein-arginine deiminase type-4 (PAD4) protein contributes to the formation of neutrophil extranuclear traps (NETs), which in turn lead to tumor growth and cancer immune escape that favors metastatic disease. The expression of PAD4 in certain types of cells, such as hematopoietic stem cells, makes the strategy of PAD4 inhibition risky due to adverse side effects.
Precede Biosciences Inc. emerged from stealth having raised $57 million in seed and series A financing to fund its genome-wide platform. The blood-based platform detects and provides critical insight into the biological activity of genes and pathways in diseased tissue to improve care and development of new therapeutics.
The dark cloud of what the U.S. FDA called potential “systemic bias” rained on Amgen Inc.’s bid for full approval of Lumakras (sotorasib), a KRAS-G12C inhibitor that was granted accelerated approval in May 2021 for locally advanced or metastatic non-small-cell lung cancer after at least one systemic therapy.
Merck Sharp & Dohme Ltd. has described ceramide glucosyltransferase (glucosylceramide synthase; GLCT-1) inhibitors reported to be useful for the treatment of cancer, Lewy body dementia, diabetes, obesity, polycystic kidney disease, neurodegeneration, lysosomal storage disease and Parkinson’s disease, among others.
Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co Ltd. have identified heterocyclic derivatives acting as Ras-related C3 botulinum toxin substrate 1 (RAC1; TC25) inhibitors reported to be useful for the treatment of melanoma, Menkes disease, rheumatoid arthritis, atherosclerosis, type 1 diabetes, Huntington’s disease and Alzheimer’s disease.
RSS
